long half-life and large variability [Regulatives / Guidelines]

posted by Achievwin – US, 2020-08-12 15:22 (41 d 00:28 ago) – Posting: # 21864
Views: 451

Welcome to the home of funky and funny pharmacokinetics where "Garbage in Gospel out" is day of life.

1. allowing long washout periods have seen studies with 4 -5 months washout.
2. other choice we can imagine is Two stage adaptive study design and including ANCOA in place of ANOVA...

want to know what other experts think?

» In short:
  • pretty long half-life
  • huge total variablity (i.e. within + between variability)
  • total variability is expected to be explained to some degree by some covariates

Complete thread:

 Admin contact
21,071 posts in 4,393 threads, 1,466 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Tuesday 15:51 CEST (Europe/Vienna)

Everybody is a Bayesian.
It’s just that some know it, and some don’t.    Trivellore Raghunathan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz